Nootropic herb (plant extract)

Bacopa Monnieri

Bacopa monnieri: a 2008 trial report states that no data were available on its pharmacokinetics, while the app lists a 6-hour half-life and 60% bioavailability.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Bacopa Monnieri after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

Bacopa monnieri is a plant that Calabrese and colleagues describe as used "for centuries in Ayurvedic medicine, either alone or in combination with other herbs, as a memory and learning enhancer, sedative, and anti-epileptic".1 The app files it as a supplement in the sub-category "Nootropic Herb", with an oral route, a typical dose of 300 to 600 mg a day and a strong evidence grade. The sources read do not agree on how strong the human evidence is. Brimson and colleagues (Scientific Reports, 2021) conclude that "there is little to no clinical evidence to suggest that B. monnieri improves the memory of healthy adults and adults with age related memory complaints".2 Kongkeaw and colleagues (Journal of Ethnopharmacology, 2014) included nine trials of at least 12 weeks, analysed 437 eligible subjects of the 518, and wrote that "Bacopa monnieri has the potential to improve cognition, particularly speed of attention".3

Aguiar and Borowski (Rejuvenation Research, 2013) review the proposed mechanisms and note that "Numerous animal and in vitro studies have been conducted".4 Their list of proposed mechanisms is antioxidant neuroprotection, acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and modulation of acetylcholine, 5-hydroxytryptamine and dopamine.4 Calabrese and colleagues conclude that whether the effect in their trial reflects a direct action on brain chemistry or "greater tolerance for frustration" "remains to be explored".1 In people, Peth-Nui and colleagues (Evidence-Based Complementary and Alternative Medicine, 2012) measured enzyme activity in plasma and reported that "The suppression of plasma AChE activity was also observed" in the group given the extract; no significant change in MAO activity was reported.5 The authors' account that the extract suppresses acetylcholinesterase in the cerebral cortex is introduced with "The mechanism for this might be that", so it is a proposal and not a measurement in brain tissue.5 Ramasamy and colleagues (Molecules, 2014) tested a standardised extract on five human cytochrome P450 enzymes with a luminescent recombinant-enzyme assay, a laboratory test with no human participants.6 The extract inhibited CYP2C19, CYP2C9 and CYP1A2 non-competitively, CYP3A4 competitively and CYP2D6 weakly, while "the bacosides showed negligible inhibition of the same isoforms".6 The authors wrote that the findings "suggest that B. monnieri extract could contribute to herb-drug interactions"; this rests on a model estimate of gut concentration, not a measured interaction in people.6

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
60%
Typical dose
300–600 mg/day
Route
Oral
Time to peak
~3 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~6 hNo figure reported; Calabrese and colleagues (2008) state that no pharmacokinetic data were available, and a Unilever-sponsored registry entry lists the half-life of Brahmi components as a planned outcome with no results shown1,7
Bioavailability60%No figure reported; the registry entry lists an absorption constant and a scan for metabolites among its planned outcomes, not bioavailability7
Time to peak~3 hNo figure reported; the registry entry lists the time of highest concentration in blood of the Brahmi components as a planned outcome7

The registry entry (NCT02462642, lead sponsor Unilever R&D, collaborator St. John's Research Institute) states that "No published data exist on the Pharmacokinetics (PK) properties of Brahmi components".7 Its pharmacokinetic part planned 8 male participants on the extract and 4 on placebo, with blood sampling "at 0,1,2,4,8,24,48 hours" and one further sample after 12 weeks of daily dosing, starting March 2010 and completing July 2010.7 The entry shows "Has Results: undefined", and no report of human plasma concentrations of Bacopa constituents was identified in PubMed or ClinicalTrials.gov on 16 November 2026.7 None of the sources read gives a half-life, bioavailability or time to peak, so the app's 6 hours, 60% and 3 hours have no reported figure beside them.

4

Human studies

Calabrese and colleagues gave the extract orally; the other records read do not all state the route, the two meta-analyses gave no extract, the extracts, standardisation and tests differ between trials, and the doses and extract strengths are in the next section.

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Stough and colleagues, Psychopharmacology 20018Double-blind, placebo-controlled, independent groups8Healthy adults; Calabrese and colleagues describe 46 volunteers aged 18–608,1Keenmind extract 300 mg; testing at baseline, 5 and 12 weeks8Improved inspection-time speed, learning rate and memory consolidation (AVLT) and state anxiety against placebo, "with maximal effects evident after 12 weeks"; the Stough record gives no adverse-event rates, and Calabrese and colleagues write that Stough et al. reported side-effects of thirst, nausea, and muscle fatigue8,1
Calabrese and colleagues, Journal of Alternative and Complementary Medicine 20081Randomised, double-blind, placebo-controlled, with a 6-week placebo run-in154 adults aged 65 or older (mean 73.5 years) without clinical signs of dementia; 48 completed, 24 per group1300 mg/day extract tablet, 50% bacosides A and B; 12 weeks1Higher AVLT delayed recall and Stroop result than placebo; depression, combined state plus trait anxiety and heart rate decreased over time for Bacopa and increased for placebo; no effects on the DAT, WAIS digit task, mood or blood pressure; 41 adverse events in total (placebo 23, Bacopa 18), of which 19 were possibly related (placebo 10, Bacopa 9)1
Morgan and Stevens, Journal of Alternative and Complementary Medicine 20109Randomised, double-blind, placebo-controlled; Lismore, Australia998 healthy participants over 55 commenced; 81 completed9BacoMind extract 300 mg/day; assessed at baseline and 12 weeks9Improved AVLT learning and recall; CFT, MAC-Q and TMT improved but group differences were not significant; gastrointestinal side-effects9
Peth-Nui and colleagues, Evidence-Based Complementary and Alternative Medicine 20125Pilot, randomised, double-blind, placebo-controlled; three groups560 healthy elderly volunteers (mean age 62.62 years; 23 males, 37 females); no dropouts5Extract 300 or 600 mg once daily; 12 weeks, plus 4 weeks after5Improved working memory, shorter N100 and P300 latencies, lower plasma AChE activity; no dose dependence shown; no serious adverse effects5
Sathyanarayanan and colleagues, Psychopharmacology 201310Randomised, double-blind, placebo-controlled, parallel1072 healthy urban adults aged 35-60, Bangalore, India10450 mg extract once daily; 12 weeks10No significant differences between groups on any cognitive measure; a trend for lower state anxiety with Bacopa10
Kumar and colleagues, Evidence-Based Complementary and Alternative Medicine 201611Randomised, double-blind, placebo-controlled, parallel1160 second-year medical students, Government Medical College, Nagpur, India11Bacognize extract 150 mg twice daily; six weeks11Digit span backwards and logical memory improved against placebo; the rest of the neuropsychological tests did not; serum calcium rose within the normal range11
Lopresti and Smith, Clinical Drug Investigation 202512Two-arm, 12-week, parallel-group, randomised, double-blind, placebo-controlled12101 adults aged 40-70 with self-reported memory and attention problems; 87 completed (47 placebo, 40 Bacopa)12Bacumen extract 300 mg daily (n = 50) or placebo (n = 51); 12 weeks12No between-group differences in verbal learning, attention or working memory; greater reduction in self-reported stress reactivity (p = 0.03); more self-reported adverse reactions with Bacopa (p = 0.024)12
Kongkeaw and colleagues, Journal of Ethnopharmacology 20143Meta-analysis of randomised, placebo-controlled trials39 studies, 518 subjects; 437 eligible subjects in the pooled analysis3Standardised extracts, chronic dosing of at least 12 weeks3Shortened Trail B time (-17.9 ms; 95% CI -24.6 to -11.2) and decreased choice reaction time (10.6 ms; 95% CI -12.1 to -9.2), with the figures printed as given3
Brimson and colleagues, Scientific Reports 20212Meta-analysis of clinical studies211 studies in healthy people for memory and attention; further studies in memory loss and Alzheimer's disease2Not pooled to one dose; studies used an array of different tests2Very little effect on memory and attention in healthy people, with the majority of the 11 outcomes showing no difference; logical memory the only outcome with a significant difference (standardised mean difference 1.11, 95% CI 0.43, 1.80), with risk of publication bias; two studies in older people complaining of memory loss had statistically significant improvements that the authors call modest2

Deeper analysis: Calabrese and colleagues, 2008

Calabrese and colleagues, of the Helfgott Research Institute, National College of Natural Medicine, Portland, Oregon, published the trial in the Journal of Alternative and Complementary Medicine in 2008.1 Three participants in each group dropped out "for reasons unrelated to the study".1 The extract was a methanol:water extract of the aerial parts, a "50:1 dry extract with a minimum of 50% bacosides A and B", and each tablet "contained the equivalent of approximately 15 g herb and 150 mg of bacosides A and B".1 The primary outcome was the delayed recall score from the Rey Auditory Verbal Learning Test.1 After adjusting for baseline cognitive deficit, "Bacopa participants had enhanced AVLT delayed word recall memory scores relative to placebo", and the text says the Bacopa group's scores "improved by over one word during the 12 weeks" while placebo scores stayed stable.1 Stroop results were similar, and depression scores, combined state plus trait anxiety scores and heart rate "decreased over time for the Bacopa group but increased for the placebo group".1 The null results were: "No effects were found on the DAT, WAIS digit task, mood, or blood pressure".1 The authors suggest the placebo group's rise in depression scores and heart rate "may reflect frustration with the repeated visits in which the same tasks are performed", rather than an actual increase in depression.1 A total of 41 adverse events were reported, 23 in the placebo group and 18 in the Bacopa group; 19 were considered "possibly related", 10 in the placebo group and 9 in the Bacopa group, and the authors conclude "there is no difference in AE between groups".1 The paper notes that the earlier Stough trial showed effects "at 12 weeks but not at 5 weeks".1 Funding: the work "was supported as pilot work" with funds from the National Institutes of Health National Center for Complementary and Alternative Medicine and the Northwest Health Foundation, and MediHerb Pty. Ltd. "provided the tablets at no cost".1 Co-author Kerry Bone is the Chairman of the Board and Director of Research and Development of MediHerb Pty. Ltd.; the paper states "He was not involved with the conduct of the study nor analysis or interpretation of the results", and the other authors report no conflicts.1 The text read has no section headed limitations; the sample was 54 people recruited by newspaper advertising and posters, and the participants had no complaints of memory impairment compared with others their age.1

Deeper analysis: Peth-Nui and colleagues, 2012

Peth-Nui and colleagues, from Khon Kaen University, Thailand, describe a "pilot study conducted as a 12-week double-blind and placebo-controlled randomized trial".5 Sixty healthy elderly volunteers received placebo or 300 or 600 mg of a crude ethanol extract once daily, assessed at baseline, every four weeks and four weeks after stopping; "No one dropped out from the study".5 At 4 weeks the 300 mg group showed "significant enhancement in both the continuity of attention and the quality of memory" against placebo, and these changes continued to week 12 and four weeks after stopping.5 Plasma AChE activity was lower in the 300 mg group from week 4 and in the 600 mg group at week 12.5 The null and secondary results were: no change in MAO activity; "no significant changes were observed at 4 weeks after the cessation of extract consumption" for N100 and P300; and "we failed to show the dependent dose".5 For safety, "The current data has not shown serious adverse effects" at 300 or 600 mg or placebo, with no hematological or biochemical changes indicating toxicity, normal ECG recordings and no dropouts.5 The paper states it was "supported in part by the National Research Council of Thailand" and two Khon Kaen University groups; its text contains no competing-interest statement, and the extract was prepared by the Faculty of Pharmaceutical Sciences at Naresuan University.5

Deeper analysis: Lopresti and Smith, 2025

In the trial by Lopresti and Smith (Clinical Drug Investigation, 2025), the 101 volunteers aged 40-70 with self-reported memory and attention problems took 300 mg daily of Bacumen (n = 50) or placebo (n = 51) for 12 weeks; 87 completed, 47 in the placebo group and 40 in the Bacopa group.12 Verbal learning, attention and working memory were the primary outcomes, and the differences between groups were not significant (p = 0.391, 0.713 and 0.610).12 Among the secondary measures, the Bacopa group had "greater reductions in overall self-reported stress reactivity (p = 0.03)" and in fatigue and stress after a demanding computer task, and there were "no group differences in changes in blood concentrations of measured markers" (brain-derived neurotrophic factor, malondialdehyde and acetylcholinesterase activity).12 The authors report "no serious adverse reactions" but "a greater frequency of self-reported adverse reactions in the Bacopa monnieri group (p = 0.024), primarily comprising digestive complaints and headaches".12 They conclude that Bacopa "did not result in greater improvements in cognitive performance" and that the stress and fatigue findings require investigation in future trials.12 The author Lopresti is managing director of Clinical Research Australia, "a contract research organization that has received research funding from nutraceutical companies", and has received presentation honoraria from nutraceutical companies; the text read states "The funder was not involved in data collection, interpretation of data, or the decision to submit it for publication" without naming the funder.12 Only the PubMed record was read for this trial, so the authors' own limitations section is not reported here.12

Other trials and funding

Stough and colleagues, Sathyanarayanan and colleagues and Morgan and Stevens are described from their PubMed records only; none of those records contains a funding statement, but the Stough and Sathyanarayanan records list the publication type "Research Support, Non-U.S. Gov't", the Morgan record names the extract maker as Natural Remedies Pvt. Ltd., and the registry entry NCT02462642 (sponsor Unilever R&D) names Krishnamachari Srinivasan as principal investigator, who is also an author of the Sathyanarayanan paper.8,10,9,7 Kumar and colleagues received the extract and matching placebo free from Pharmanza Herbal Pvt. Ltd., state that raw data were not made available to that company, and declare no conflict of interest.11 Their own caution is that "the confounding factors like diet, stress, and anxiety were not eliminated since the students continued with their routine college lifestyle", and the serum cholesterol and HDL changes in the Bacopa group were "statistically nonsignificant" against placebo.11 Two participants were dropped for noncompliance, and "the final sample in the two groups is not the same".11

Deeper analysis: the meta-analyses

Kongkeaw and colleagues (Naresuan University, Thailand) searched databases to June 2013 and included randomised, placebo-controlled trials of chronic dosing of at least 12 weeks; the authors rated "Overall quality of all included trials" as "low risk of bias".3 Pooled results were a shortened Trail B test (-17.9 ms; 95% CI -24.6 to -11.2; p below 0.001) and a decreased choice reaction time (10.6 ms; 95% CI -12.1 to -9.2; p below 0.001).3 The authors write that "only a large well designed 'head-to-head' trial against an existing medication will provide definitive data on its efficacy".3 The PubMed record gives no funding statement or author ties for this meta-analysis.3 For healthy people Brimson and colleagues wrote that "no two studies found statistically significant changes in the same two tests", and that most studies "only found one or two measures of memory to have a statistically significant difference, and even then, these changes were small".2 The authors raise a limitation on multiple testing: "These studies could suffer from familywise (type one) errors, as so many variables were being investigated, there is a greater chance of finding significance in at least one of them".2 For Alzheimer's disease they note that the one double-blind placebo-controlled study "used a poly-herb formulation", so effects "cannot be directly attributed to B. monnieri per se".2 Two authors were funded by postdoctoral fellowships from Chulalongkorn University funds, and the paper states "The authors declare no competing interests".2

5

Doses reported in studies and on labels

No product label for Bacopa monnieri was identified in DailyMed, so the table lists doses reported in trials, a registry entry and a reference chapter. The app's typical range is 300 to 600 mg a day.13

Table 5.1Doses reported in studies and on labels9 rows
SourcePreparationDoseLength and people
Stough and colleagues 20018Keenmind extract300 mgTests at baseline, 5 and 12 weeks; healthy adults8
Calabrese and colleagues 2008150:1 dry extract, minimum 50% bacosides A and B, in a tablet300 mg/day, oral; about 150 mg of bacosides A and B per tablet12 weeks; 54 adults aged 65 or older1
Morgan and Stevens 20109BacoMind extract300 mg/day12 weeks; 98 healthy participants over 559
Peth-Nui and colleagues 20125Crude ethanol extract, total saponins 5% (w/w) by HPLC300 or 600 mg once daily, tablet12 weeks; 60 healthy elderly volunteers5
Sathyanarayanan and colleagues 201310Brahmi extract450 mg, single daily dose12 weeks; 72 healthy adults aged 35-6010
Registry entry NCT02462642 (Unilever R&D)7Brahmi extract, 225 mg per hard gelatin capsuleTwo capsules per day12 weeks; planned 36 per arm for cognition and 8 on extract for pharmacokinetics7
Kumar and colleagues 201611Bacognize extract, 45% Bacopa saponins by UV spectrophotometry150 mg twice dailySix weeks; 60 medical students11
Lopresti and Smith 202512Bacumen extract300 mg daily12 weeks; 101 adults aged 40-7012
StatPearls chapter13Extracts usually standardised to 24% to 55% bacosides300 to 450 mg per day for adults; 225 mg daily for up to 6 months in children aged 6 to 12Typical ranges "used in traditional medicine and modern clinical trials"13

The app's note gives 50% bacosides as the most studied standardisation; among the trials above, Calabrese and colleagues report a minimum of 50% bacosides A and B, Peth-Nui and colleagues 5% total saponins and Kumar and colleagues 45% saponins, so extract strength is not uniform across trials.1,5,11

Morgan and Stevens report that "Bacopa caused GIT side-effects of increased stool frequency, abdominal cramps, and nausea".9 In Calabrese and colleagues' trial 41 adverse events were reported, 23 on placebo and 18 on Bacopa, of which 19 were considered possibly related (10 placebo, 9 Bacopa); the authors found no difference between groups, and they describe the possibly related events (Bacopa n = 9, placebo n = 10) as primarily stomach upset.1 Lopresti and Smith report no serious adverse reactions and more self-reported adverse reactions with Bacopa (p = 0.024), mainly digestive complaints and headaches.12 Brimson and colleagues summarise that "The majority of the studies showed only minor incidence of side effects", that two studies gave no details, and that gastrointestinal effects "were predominantly seen in the B. monnieri groups as opposed to the placebo".2 Brimson and colleagues also report that Morgan et al. had 13 dropouts from the B. monnieri group and 4 from the placebo group, and that among dropouts after the initial baseline test across the 11 studies, nine were due to side effects and four were for reasons unrelated to the study.2 The StatPearls chapter states that "The most common side effects are gastrointestinal, including increased stool frequency, nausea, and abdominal cramps", and that "Bacopa is mildly sedating".13 The chapter's animal findings include "reversible suppression of spermatogenesis and fertility in Parkes (P) strain mice" and thyroxine (T4) raised "in mice by about 40%"; these are animal results and no human equivalent is reported in the chapter.13 Aguiar and Borowski conclude that Bacopa "appears to exhibit low toxicity in model organisms and humans; however, long-term studies of toxicity in humans have yet to be conducted".4

7

Bloodwork and markers

The app lists no health markers to monitor for Bacopa monnieri. In Kumar and colleagues' six-week trial, serum calcium rose significantly in the Bacopa group and "still" stayed within the normal range; the authors cite earlier reports of calcium antagonist activity in rabbit and guinea pig tissue.11 Lopresti and Smith measured brain-derived neurotrophic factor, malondialdehyde and acetylcholinesterase activity in blood and report no group differences in their changes.12

8

Regulatory and anti-doping status

A DailyMed search for "Bacopa monnieri" on 16 November 2026 matched 0 labels, and no regulator's assessment document for Bacopa monnieri was identified in the sources read. The World Anti-Doping Agency 2026 Prohibited List text read has no entry naming Bacopa, Brahmi or monnieri.14 The list's S0 class covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", and the sources read do not say how it applies to a plant extract.14

No human half-life, bioavailability, time to peak or plasma concentration of Bacopa constituents was identified in the sources read, and the app's 6 hours, 60% and 3 hours rest on none of them. The registry entry for the pharmacokinetic part of NCT02462642 shows no posted results.7 Whether the cognitive findings depend on the extract is unclear: the trials above used extracts with 5%, 45% and 50% saponin or bacoside content, and Peth-Nui and colleagues did not show a dose relationship between 300 and 600 mg.5,11,1 Brimson and colleagues call for larger, longer studies that go head to head with standard drugs and use the same set of neuropsychological tests.2

What is the half-life of Bacopa monnieri?

No human half-life figure for Bacopa monnieri was identified in the sources read, and the app lists about 6 hours.1,7 A registry entry lists the half-life of Brahmi components as a planned outcome and shows no results.7

What is the bioavailability of Bacopa monnieri?

No bioavailability figure was identified in the sources read, and the app lists 60%.1,7

How long does Bacopa monnieri take to reach peak blood levels?

No time-to-peak figure was identified in the sources read, and the app lists about 3 hours.7

Is Bacopa monnieri banned by WADA?

The World Anti-Doping Agency 2026 Prohibited List text read has no entry naming Bacopa, Brahmi or monnieri.14 The list's S0 class for non-approved substances does not name it, and the sources read do not say how that class applies to a plant extract.14

Is there an FDA-approved Bacopa monnieri drug label?

A DailyMed search for "Bacopa monnieri" on 16 November 2026 matched 0 labels.

What side effects have trials of Bacopa monnieri reported?

Morgan and Stevens report gastrointestinal side-effects of increased stool frequency, abdominal cramps and nausea.9 Lopresti and Smith report more self-reported adverse reactions with Bacopa than placebo (p = 0.024), mainly digestive complaints and headaches, and no serious adverse reactions.12 Calabrese and colleagues report 18 adverse events on Bacopa and 23 on placebo and no difference between groups.1

Does Bacopa monnieri improve memory in trials?

Results differ between trials: Calabrese and colleagues report higher delayed recall than placebo in 54 adults aged 65 or older, while Sathyanarayanan and colleagues report no significant difference on any cognitive measure in 72 healthy adults.1,10 Brimson and colleagues conclude there is "little to no clinical evidence" of improved memory in healthy adults and adults with age-related memory complaints, while Kongkeaw and colleagues report shorter Trail B and choice reaction times.2,3

Does Bacopa monnieri affect cytochrome P450 enzymes?

In a laboratory test with recombinant human enzymes, a Bacopa monnieri extract inhibited CYP2C19, CYP2C9, CYP1A2 and CYP3A4 and weakly inhibited CYP2D6.6 The bacosides alone showed negligible inhibition, and the study did not measure an interaction in people.6

12

References

  1. Calabrese C, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2008. PMID 18611150
  2. Brimson JM, et al. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. Sci Rep 2021. PMID 33436817
  3. Kongkeaw C, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol 2014. PMID 24252493
  4. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res 2013. PMID 23772955
  5. Peth-Nui T, et al. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers. Evid Based Complement Alternat Med 2012. PMID 23320031
  6. Ramasamy S, et al. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules 2014. PMID 24566323
  7. Unilever R&D. Effect of Bacopa Monniera Extract on Cognition and Anxiety and Exploration of PK Properties (NCT02462642). ClinicalTrials.gov registry entry. NCT02462642
  8. Stough C, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 2001. PMID 11498727
  9. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010. PMID 20590480
  10. Sathyanarayanan V, et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Psychopharmacology 2013. PMID 23354535
  11. Kumar N, et al. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Evid Based Complement Alternat Med 2016. PMID 27803728
  12. Lopresti AL, Smith SJ. The Effects of a Bacopa monnieri Extract (Bacumen) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Drug Investig 2025. PMID 41091332
  13. Bacopa monnieri. StatPearls, NCBI Bookshelf. StatPearls chapter
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list